Text Size

Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00274716
First received: January 10, 2006
Last updated: April 24, 2008
Last verified: April 2008
History of Changes
  Purpose

The objective of this study is to evaluate the safety and efficacy of two investigational drugs in lowering blood pressure and body weight in patients with hypertension (high blood pressure).

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).


Condition Intervention Phase
Hypertension
 Drug: MK0736
Drug: MK0916
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MK0736 and MK0916 in Hypertensive Patients

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:
  • Reduction in blood pressure, safety and tolerability

Secondary Outcome Measures:
  • Waist circumference, dose comparison

Study Start Date: November 2005
Study Completion Date: January 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hypertension SBP </= 160mm Hg and DBP: 90-105mm Hg

Exclusion Criteria:

  • Pre-menopausal women
  • patients currently taking more than two (2) blood pressure lowering medications
  • Body Mas Index (BMI)>40 kg/m2 (morbidly obese patients)
  • History of Alcohol abuse (<3 Years)
  • History of diabetes,chronic kidney disease, Active liver disease, recent heart attack or stroke
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00274716

Sponsors and Collaborators
Merck
Investigators
Study Director: Medical Monitor Merck
  More Information

No publications provided by Merck

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
ClinicalTrials.gov Identifier: NCT00274716     History of Changes
Other Study ID Numbers: 2006_004, MK0736-003
Study First Received: January 10, 2006
Last Updated: April 24, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 23, 2013